Statements (37)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:depression
|
| gptkbp:antagonist |
serotonin 5-HT2 A receptors
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
brexpiprazole
|
| gptkbp:class |
atypical antipsychotic
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:dosage_form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rexulti
|
| gptkbp:ingredients |
brexpiprazole
|
| gptkbp:invention |
2026
|
| gptkbp:manufacturer |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:marketed_as |
gptkb:2015
|
| gptkbp:mechanism_of_action |
partial agonist at dopamine D2 receptors
partial agonist at serotonin 5-HT1 A receptors |
| gptkbp:requires |
gptkb:true
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
anxiety
fatigue nausea restlessness drowsiness insomnia constipation dry mouth weight gain blurred vision |
| gptkbp:strength |
1 mg
0.5 mg 2 mg 3 mg 4 mg 0.25 mg |
| gptkbp:used_for |
treatment of schizophrenia
treatment of major depressive disorder |
| gptkbp:bfsParent |
gptkb:Lundbeck_A/_S
gptkb:Otsuka_Pharmaceutical |
| gptkbp:bfsLayer |
7
|